Safety and efficacy of cryopreserved autologous platelet concentrates in HLA-alloimmunized patients with hematologic malignancies.

Details

Serval ID
serval:BIB_0FBF2C6F7B79
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Safety and efficacy of cryopreserved autologous platelet concentrates in HLA-alloimmunized patients with hematologic malignancies.
Journal
Transfusion
Author(s)
Gerber B., Alberio L., Rochat S., Stenner F., Manz M.G., Buser A., Schanz U., Stussi G.
ISSN
1537-2995 (Electronic)
ISSN-L
0041-1132
Publication state
Published
Issued date
2016
Peer-reviewed
Oui
Volume
56
Number
10
Pages
2426-2437
Language
english
Notes
Publication types: ARTICLE
Publication Status: ppublish
Abstract
BACKGROUND: Curative chemotherapy approaches in patients with malignancies and platelet (PLT) transfusion refractoriness due to alloimmunization may be hampered by the lack of suitable PLT donors. For these patients, transfusion of cryopreserved autologous PLTs is an option, but is time- and resource-consuming. We aimed at further simplifying this process.
STUDY DESIGN AND METHODS: A retrospective single-center analysis was conducted on the transfusion of cryopreserved autologous PLTs in nine female alloimmunized, PLT transfusion-refractory patients treated for acute leukemia (n = 8) and non-Hodgkin's lymphoma (n = 1). No additional processing was used before transfusion, and most notably, washing and centrifugation steps were omitted. Clinical efficacy and safety, as well as a flow cytometric assessment of structural and functional PLT changes, were analyzed.
RESULTS: A total of 40 autologous PLT concentrates were thawed at bedside and transfused a median of 32 (range, 9 to 994) days after cryopreservation. No major bleeds and no severe dimethyl sulfoxide toxicity were observed. The median PLT count increments did not differ 1 and 18 to 24 hours after transfusion and reached 6 × 10(9) /L (interquartile range [IQR], 3 × 10(9) -7.5 × 10(9) /L) and 6 × 10(9) /L (IQR, 2.5 × 10(9) -9.5 × 10(9) /L), respectively. Cryopreservation resulted in partial activation of one-third of the PLTs. In vitro stimulation with strong agonists induced additional full activation of cryopreserved PLTs: median, 55% (IQR, 42%-60%) after thrombin and 39% (IQR, 36%-39%) after convulxin.
CONCLUSION: The transfusion of cryopreserved autologous PLTs is feasible and safe. Despite the cryopreservation process, PLT functionality is partially maintained.
Pubmed
Web of science
Create date
01/07/2016 9:57
Last modification date
20/08/2019 12:36
Usage data